Equities

Adalta Ltd

1AD:ASX

Adalta Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.019
  • Today's Change0.00 / 0.00%
  • Shares traded475.52k
  • 1 Year change-5.00%
  • Beta0.7837
Data delayed at least 20 minutes, as of Sep 20 2024 05:44 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Adalta Ltd's revenues fell -49.47% from 3.53m to 1.78m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 4.85m to a larger loss of 5.38m.
Gross margin--
Net profit margin-301.55%
Operating margin-295.76%
Return on assets-80.88%
Return on equity-273.13%
Return on investment-203.94%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Adalta Ltd fell by 1.66m. Cash Flow from Financing totalled 3.67m or 205.44% of revenues. In addition the company used 5.26m for operations while cash used for investing totalled 62.40k.
Cash flow per share-0.0108
Price/Cash flow per share--
Book value per share0.0034
Tangible book value per share0.0034
More ▼

Balance sheet in AUDView more

Adalta Ltd has a Debt to Total Capital ratio of 57.12%.
Current ratio2.38
Quick ratio--
Total debt/total equity1.33
Total debt/total capital0.5712
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.